Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2015-09-23
Target enrollment:
Participant gender:
Summary
Objective of this study is to characterize the steady-state pharmacokinetics (PK) of
thalidomide when given orally as monotherapy to subjects with multiple myeloma.